文献速递头颈外科

选择性MYB启动子活性是头颈部腺样囊性癌的潜在预后生物标志物

Alternative MYB Promoter Activity Is a Potential Prognostic Biomarker in Head and Neck Adenoid Cystic Carcinoma.
PubMed 文献 · Head Neck · 2025-02-25

该研究在28例腺样囊性癌(ACC)中采用MYB外显子特异性qPCR检测选择性MYB启动子(MYB TSS2)活性,并分析其与总生存(OS)及基因组、转录组特征的关系。结果显示MYB TSS2高表达组OS显著短于低表达组(p=0.02),多变量分析中MYB TSS2活性是独立于肿瘤分级和NOTCH1突变状态的OS预后标志(p=0.03)。

要点

  • MYB TSS2高表达组ACC患者的总生存显著短于低表达组(p=0.02)。
  • 多变量分析显示MYB TSS2活性是独立于肿瘤分级和NOTCH1突变状态的OS预后标志(p=0.03)。
  • 伴6q缺失的ACC中MYB TSS2活性显著高于无缺失者(p=0.04),且高活性肿瘤细胞周期基因和已知MYB靶基因表达增加。

核心结论

  • 选择性MYB启动子活性是ACC新的潜在预后生物标志物,并进一步强化了MYB靶向治疗的相关性。
  • MYB TSS2高表达的初治肿瘤比MYB TSS2低表达肿瘤更具侵袭性且预后更差。

研究设计与样本

  • 在28例ACC中采用MYB外显子特异性qPCR检测MYB TSS2活性,并进行总生存(OS)和风险分析以评估MYB TSS2高、低病例的结局。
  • 同时分析ACC的基因组和转录组特征与MYB TSS2活性的关系。

主要发现

  • MYB TSS2高表达组患者OS显著短于MYB TSS2低表达组(p=0.02)。
  • 多变量分析表明MYB TSS2活性是OS的显著预后生物标志物(p=0.03),独立于肿瘤分级和NOTCH1突变状态。
  • 伴6q缺失的ACC中MYB TSS2活性显著高于无6q缺失者(p=0.04)。
  • MYB TSS2高表达肿瘤中细胞周期基因和已知MYB靶基因表达增加。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Adenoid cystic carcinoma (ACC) is an aggressive therapy-resistant head and neck cancer with a high frequency of local recurrences and distant metastases. Activation of the MYB gene, encoding an oncogenic master transcription factor, is the key genomic hallmark of ACC and a potential therapeutic target. Here, we have investigated the clinical significance of alternative MYB promoter (MYB TSS2) activation in primary ACCs. METHODS: MYB TSS2 activity was studied in 28 ACCs using MYB exon-specific qPCR assays. Overall survival (OS) and risk analyses were done to estimate the outcomes of MYB TSS2 high and low cases, respectively. The genomic and transcriptomic profiles of the ACCs were also analyzed in relation to MYB TSS2 activity. RESULTS: OS was significantly shorter among patients in the MYB TSS2 high group compared to the MYB TSS2 low group (p = 0.02). Multivariate analysis indicated that MYB TSS2 activity was a significant prognostic biomarker for OS (p = 0.03) that was independent of tumor grade and NOTCH1 mutation status. There was markedly higher MYB TSS2 activity in ACCs with 6q deletions compared to those without deletions (p = 0.04). Moreover, MYB TSS2 high tumors had an increased expression of cell cycle genes and known MYB target genes. CONCLUSION: The study demonstrates that alternative MYB promoter activity is a new potential prognostic biomarker for ACC and further strengthens the relevance of MYB-targeted therapy. Our findings indicate that MYB TSS2 high primary tumors are more aggressive and have a worse prognosis than MYB TSS2 low tumors.

来源:Head Neck,查看原文。版权归原作者所有。

引用

  1. Jäwert F, Fehr A, Persson M, et al. Alternative MYB Promoter Activity Is a Potential Prognostic Biomarker in Head and Neck Adenoid Cystic Carcinoma. Head Neck. 2025. PMID: 39996285. doi:10.1002/hed.28123

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。